Regulatory Roundup - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup
Compounding, tracking legislation moves forward


Pharmaceutical Technology
Volume 37, Issue 7, pp. 26

Compounding, tracking legislation moves forward
Bills setting new rules for drug compounding and distribution through the supply chain are moving forward in the House and Senate, but clear divergence on specific provisions makes the final outcome uncertain. A bipartisan Senate measure would give FDA greater authority to regulate a new category of commercial compounders—large-scale operators that sell risky injectibles across state lines without prior individual prescriptions, while leaving "traditional" pharmacy compounders under state law. The Senate Health, Education, Labor & Pensions (HELP) Committee linked this compounding bill to a measure establishing an electronic tracking system for prescription drugs, starting with lot-level tracking and shifting to a unit-level traceability system over 10 years.

The House recently approved legislation that establishes an "enhanced" drug-tracking system, but without any clear path to unit-level reporting. House Republicans, however, propose only minor changes to FDA control over compounders, claiming that the agency has sufficient authority to regulate illegal operators and should do that more effectively. Both House and Senate track-and-trace bills pre-empt state laws, which has drawn opposition from California members of Congress who oppose any federal drug-tracking system that is less stringent than the one set for implementation in California. Congressional leaders have talked about enacting legislation by August, but it may take longer.

Medicare drug pricing
The 10-year anniversary of the Medicare prescription drug program (Part D) has brought praise for how it has extended access to medicines for nearly 50 million beneficiaries, along with questions about its costs and limitations. An analysis by consultants Avalere Health for drugmaker UCB finds that Part D plans cover fewer anticonvulsant drugs than commercial insurance plans and impose higher cost sharing that limits access (1). Meanwhile, the Senate Special Committee on Aging has asked the Government Accountability Office (GAO) to examine Part D spending, oversight of coverage and pricing information, and the program's potential for fraud and abuse. Sen. Ben Nelson of Florida, chairman of the Committee on Aging, seeks support for legislation requiring drug manufacturers to pay Medicaid rebates on medicines provided to low income "dual eligible" beneficiaries. That policy is calculated to raise $140 billion over 10 years and faces strong opposition from pharmaceutical companies.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here